Wugen is pioneering a new class of memory natural killer (NK) cell therapies using their proprietary MonetaTM platform and deep genomic engineering expertise. Their lead program, WU-NK-101, has shown promising efficacy and safety in Phase 1b clinical trials for acute myeloid leukemia (AML). Wugen's off-the-shelf NK cell and CAR-T therapies address the needs of patients with solid tumors, AML, and T-cell malignancies, providing a potential solution to combat life-threatening tumors. Founded in 2018 and based in Saint Louis, Missouri, Wugen is focused on advancing cell therapies for the treatment of various cancers.